ABCL635 / AbCellera - LARVOL DELTA

AbCellera Reports Full Year 2024 Business Results (Businesswire) - "'We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy,'...As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635 and ABCL575, and to start activities in our new clinical manufacturing facility.'...Revenue – Total revenue was $28.8 million, compared to $38.0 million in 2023. In both periods, the majority of revenues were research fees generated by our partnerships."

Commercial • New P1 trial • Immunology • Metabolic Disorders

AbCellera Reports Q2 2024 Business Results (Businesswire) - "Q2 2024 Business Summary: ABCL635 and ABCL575 remain on track for anticipated Clinical Trial Applications (CTAs) in the second quarter of 2025."

New trial • Atopic Dermatitis